Kyverna Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Kyverna Therapeutics, Inc. (KYTX) reported Increase (Decrease) in Prepaid Expense and Other Assets of $526.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $592.00K.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$66.00K, a 117.37% decline year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$58.00K, a 106.95% decline year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $1.14M, a 5.33% decline year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$893.00K, a 159.49% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $1.50M, a 25.92% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.19M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $592.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $526.00K 10-Q · filed 2026-08-11 | $468.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$66.00K 10-Q · filed 2026-05-12 | -$124.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.01M derived: sum of 3 quarters · filed 2026-05-12 | -$1.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.08M derived: sum of 2 quarters · filed 2026-03-26 | -$1.27M derived: sum of 3 quarters · filed 2026-08-11 | -$893.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.22M derived: sum of 2 quarters · filed 2026-08-11 | -$835.00K 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.97M 10-Q · filed 2026-08-11 | -$1.14M derived: sum of 3 quarters · filed 2026-08-11 | $64.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $380.00K 10-Q · filed 2026-05-12 | $1.22M derived: sum of 2 quarters · filed 2026-05-12 | $2.42M derived: sum of 3 quarters · filed 2026-05-12 | -$692.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $835.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.04M derived: sum of 2 quarters · filed 2026-03-26 | -$1.07M derived: sum of 3 quarters · filed 2026-03-26 | $1.50M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.91M derived: sum of 2 quarters · filed 2025-11-12 | $666.00K 10-Q · filed 2025-11-12 | $1.65M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$535.00K 10-Q · filed 2025-08-12 | $450.00K derived: sum of 3 quarters · filed 2025-08-12 | -$242.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.57M 10-Q · filed 2025-05-13 | $3.56M derived: sum of 2 quarters · filed 2025-05-13 | $2.87M derived: sum of 3 quarters · filed 2025-05-13 | $3.60M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $293.00K derived: sum of 2 quarters · filed 2025-03-27 | $1.03M derived: sum of 3 quarters · filed 2025-03-27 | $1.19M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $46.00K derived: sum of 2 quarters · filed 2024-11-13 | $207.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $738.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $899.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $161.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |